Selected research
Industry Growth & Trends
Global Restless Legs Syndrome Industry Growth and Trends Forecast to 2032
Market perspective
According to APO Research, the global Restless Legs Syndrome market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The North America market for Restless Legs Syndrome is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.
The Europe market for Restless Legs Syndrome is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Restless Legs Syndrome is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global companies in the Restless Legs Syndrome market include UCB SA, Omeros Corporation, Manhattan Pharmaceuticals, Ligand Pharmaceuticals Incorporated, Kyowa Hakko Kirin Co., Jazz Pharmaceuticals, Inc., GlaxoSmithKline plc., Boehringer Ingelheim GmbH and axxonis Pharma AG, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report provides a structured, data-driven view of the global Restless Legs Syndrome market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The Restless Legs Syndrome market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Restless Legs Syndrome market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Restless Legs Syndrome.
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading companies in the global Restless Legs Syndrome market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
Restless Legs Syndrome Market by Company
UCB SA
Omeros Corporation
Manhattan Pharmaceuticals
Ligand Pharmaceuticals Incorporated
Kyowa Hakko Kirin Co.
Jazz Pharmaceuticals, Inc.
GlaxoSmithKline plc.
Boehringer Ingelheim GmbH
axxonis Pharma AG
Astellas
Arbor Pharmaceuticals
Restless Legs Syndrome Segment by Type
Pharmacological Therapy
Non-Pharmacological Therapy
Restless Legs Syndrome Segment by Application
Above 50 Years Old
Below 35 Years Old
From 35 to 50 Years Old
Restless Legs Syndrome Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Restless Legs Syndrome market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Restless Legs Syndrome and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Restless Legs Syndrome.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of Restless Legs Syndrome companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Pharmacological Therapy
- Non-Pharmacological Therapy
Applications
- Above 50 Years Old
- Below 35 Years Old
- From 35 to 50 Years Old
Companies covered
- UCB SA
- Omeros Corporation
- Manhattan Pharmaceuticals
- Ligand Pharmaceuticals Incorporated
- Kyowa Hakko Kirin Co.
- Jazz Pharmaceuticals, Inc.
- GlaxoSmithKline plc.
- Boehringer Ingelheim GmbH
- axxonis Pharma AG
- Astellas
- Arbor Pharmaceuticals
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.3 Global Restless Legs Syndrome Market Size Overview by Region 2021 VS 2025 VS 2032
- 1.4 Global Restless Legs Syndrome Market Size by Region (2021-2032)
- 1.4.1 Global Restless Legs Syndrome Market Size by Region (2021-2026)
- 1.4.2 Global Restless Legs Syndrome Market Size by Region (2027-2032)
- 1.5 Key Regions Restless Legs Syndrome Market Size (2021-2032)
- 1.5.1 North America Restless Legs Syndrome Market Size Growth Rate (2021-2032)
- 1.5.2 Europe Restless Legs Syndrome Market Size Growth Rate (2021-2032)
- 1.5.3 Asia-Pacific Restless Legs Syndrome Market Size Growth Rate (2021-2032)
- 1.5.4 South America Restless Legs Syndrome Market Size Growth Rate (2021-2032)
- 1.5.5 Middle East & Africa Restless Legs Syndrome Market Size Growth Rate (2021-2032)
2 Restless Legs Syndrome Market by Type
- 2.1 Type Introduction
- 2.1.1 Pharmacological Therapy
- 2.1.2 Non-Pharmacological Therapy
- 2.2 Global Restless Legs Syndrome Market Size by Type
- 2.2.1 Global Restless Legs Syndrome Market Size Overview by Type (2021-2032)
- 2.2.2 Global Restless Legs Syndrome Historic Market Size Review by Type (2021-2026)
- 2.2.3 Global Restless Legs Syndrome Market Size Forecasted by Type (2027-2032)
- 2.3 Global Restless Legs Syndrome Market Size by Regions
- 2.3.1 North America Restless Legs Syndrome Market Size Breakdown by Type (2021-2026)
- 2.3.2 Europe Restless Legs Syndrome Market Size Breakdown by Type (2021-2026)
- 2.3.3 Asia-Pacific Restless Legs Syndrome Market Size Breakdown by Type (2021-2026)
- 2.3.4 South America Restless Legs Syndrome Market Size Breakdown by Type (2021-2026)
- 2.3.5 Middle East and Africa Restless Legs Syndrome Market Size Breakdown by Type (2021-2026)
3 Restless Legs Syndrome Market by Application
- 3.1 Type Introduction
- 3.1.1 Above 50 Years Old
- 3.1.2 Below 35 Years Old
- 3.1.3 From 35 to 50 Years Old
- 3.2 Global Restless Legs Syndrome Market Size by Application
- 3.2.1 Global Restless Legs Syndrome Market Size Overview by Application (2021-2032)
- 3.2.2 Global Restless Legs Syndrome Historic Market Size Review by Application (2021-2026)
- 3.2.3 Global Restless Legs Syndrome Market Size Forecasted by Application (2027-2032)
- 3.3 Global Restless Legs Syndrome Market Size by Regions
- 3.3.1 North America Restless Legs Syndrome Market Size Breakdown by Application (2021-2026)
- 3.3.2 Europe Restless Legs Syndrome Market Size Breakdown by Application (2021-2026)
- 3.3.3 Asia-Pacific Restless Legs Syndrome Market Size Breakdown by Application (2021-2026)
- 3.3.4 South America Restless Legs Syndrome Market Size Breakdown by Application (2021-2026)
- 3.3.5 Middle East and Africa Restless Legs Syndrome Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
- 4.1 Restless Legs Syndrome Industry Trends
- 4.2 Restless Legs Syndrome Industry Drivers
- 4.3 Restless Legs Syndrome Industry Opportunities and Challenges
- 4.4 Restless Legs Syndrome Industry Restraints
5 Competitive Insights by Company
- 5.1 Global Top Players by Restless Legs Syndrome Revenue (2021-2026)
- 5.2 Global Restless Legs Syndrome Industry Company Ranking, 2024 VS 2025 VS 2026
- 5.3 Global Restless Legs Syndrome Key Company Headquarters & Area Served
- 5.4 Global Restless Legs Syndrome Company, Product Type & Application
- 5.5 Global Restless Legs Syndrome Company Commercialization Time
- 5.6 Market Competitive Analysis
- 5.6.1 Global Restless Legs Syndrome Market CR5 and HHI
- 5.6.2 Global Top 5 and 10 Restless Legs Syndrome Players Market Share by Revenue in 2025
- 5.6.3 2025 Restless Legs Syndrome Tier 1, Tier 2, and Tier 3
6 Company Profiles
- 6.1 UCB SA
- 6.1.1 UCB SA Company Information
- 6.1.2 UCB SA Business Overview
- 6.1.3 UCB SA Restless Legs Syndrome Revenue, Global Share and Gross Margin (2021-2026)
- 6.1.4 UCB SA Restless Legs Syndrome Product Portfolio
- 6.1.5 UCB SA Recent Developments
- 6.2 Omeros Corporation
- 6.2.1 Omeros Corporation Company Information
- 6.2.2 Omeros Corporation Business Overview
- 6.2.3 Omeros Corporation Restless Legs Syndrome Revenue, Global Share and Gross Margin (2021-2026)
- 6.2.4 Omeros Corporation Restless Legs Syndrome Product Portfolio
- 6.2.5 Omeros Corporation Recent Developments
- 6.3 Manhattan Pharmaceuticals
- 6.3.1 Manhattan Pharmaceuticals Company Information
- 6.3.2 Manhattan Pharmaceuticals Business Overview
- 6.3.3 Manhattan Pharmaceuticals Restless Legs Syndrome Revenue, Global Share and Gross Margin (2021-2026)
- 6.3.4 Manhattan Pharmaceuticals Restless Legs Syndrome Product Portfolio
- 6.3.5 Manhattan Pharmaceuticals Recent Developments
- 6.4 Ligand Pharmaceuticals Incorporated
- 6.4.1 Ligand Pharmaceuticals Incorporated Company Information
- 6.4.2 Ligand Pharmaceuticals Incorporated Business Overview
- 6.4.3 Ligand Pharmaceuticals Incorporated Restless Legs Syndrome Revenue, Global Share and Gross Margin (2021-2026)
- 6.4.4 Ligand Pharmaceuticals Incorporated Restless Legs Syndrome Product Portfolio
- 6.4.5 Ligand Pharmaceuticals Incorporated Recent Developments
- 6.5 Kyowa Hakko Kirin Co.
- 6.5.1 Kyowa Hakko Kirin Co. Company Information
- 6.5.2 Kyowa Hakko Kirin Co. Business Overview
- 6.5.3 Kyowa Hakko Kirin Co. Restless Legs Syndrome Revenue, Global Share and Gross Margin (2021-2026)
- 6.5.4 Kyowa Hakko Kirin Co. Restless Legs Syndrome Product Portfolio
- 6.5.5 Kyowa Hakko Kirin Co. Recent Developments
- 6.6 Jazz Pharmaceuticals, Inc.
- 6.6.1 Jazz Pharmaceuticals, Inc. Company Information
- 6.6.2 Jazz Pharmaceuticals, Inc. Business Overview
- 6.6.3 Jazz Pharmaceuticals, Inc. Restless Legs Syndrome Revenue, Global Share and Gross Margin (2021-2026)
- 6.6.4 Jazz Pharmaceuticals, Inc. Restless Legs Syndrome Product Portfolio
- 6.6.5 Jazz Pharmaceuticals, Inc. Recent Developments
- 6.7 GlaxoSmithKline plc.
- 6.7.1 GlaxoSmithKline plc. Company Information
- 6.7.2 GlaxoSmithKline plc. Business Overview
- 6.7.3 GlaxoSmithKline plc. Restless Legs Syndrome Revenue, Global Share and Gross Margin (2021-2026)
- 6.7.4 GlaxoSmithKline plc. Restless Legs Syndrome Product Portfolio
- 6.7.5 GlaxoSmithKline plc. Recent Developments
- 6.8 Boehringer Ingelheim GmbH
- 6.8.1 Boehringer Ingelheim GmbH Company Information
- 6.8.2 Boehringer Ingelheim GmbH Business Overview
- 6.8.3 Boehringer Ingelheim GmbH Restless Legs Syndrome Revenue, Global Share and Gross Margin (2021-2026)
- 6.8.4 Boehringer Ingelheim GmbH Restless Legs Syndrome Product Portfolio
- 6.8.5 Boehringer Ingelheim GmbH Recent Developments
- 6.9 axxonis Pharma AG
- 6.9.1 axxonis Pharma AG Company Information
- 6.9.2 axxonis Pharma AG Business Overview
- 6.9.3 axxonis Pharma AG Restless Legs Syndrome Revenue, Global Share and Gross Margin (2021-2026)
- 6.9.4 axxonis Pharma AG Restless Legs Syndrome Product Portfolio
- 6.9.5 axxonis Pharma AG Recent Developments
- 6.10 Astellas
- 6.10.1 Astellas Company Information
- 6.10.2 Astellas Business Overview
- 6.10.3 Astellas Restless Legs Syndrome Revenue, Global Share and Gross Margin (2021-2026)
- 6.10.4 Astellas Restless Legs Syndrome Product Portfolio
- 6.10.5 Astellas Recent Developments
- 6.11 Arbor Pharmaceuticals
- 6.11.1 Arbor Pharmaceuticals Company Information
- 6.11.2 Arbor Pharmaceuticals Business Overview
- 6.11.3 Arbor Pharmaceuticals Restless Legs Syndrome Revenue, Global Share and Gross Margin (2021-2026)
- 6.11.4 Arbor Pharmaceuticals Restless Legs Syndrome Product Portfolio
- 6.11.5 Arbor Pharmaceuticals Recent Developments
7 North America
- 7.1 North America Restless Legs Syndrome Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2 North America Restless Legs Syndrome Market Size by Country (2021-2026)
- 7.3 North America Restless Legs Syndrome Market Size Forecast by Country (2027-2032)
8 Europe
- 8.1 Europe Restless Legs Syndrome Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2 Europe Restless Legs Syndrome Market Size by Country (2021-2026)
- 8.3 Europe Restless Legs Syndrome Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific Restless Legs Syndrome Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2 Asia-Pacific Restless Legs Syndrome Market Size by Country (2021-2026)
- 9.3 Asia-Pacific Restless Legs Syndrome Market Size Forecast by Country (2027-2032)
10 South America
- 10.1 South America Restless Legs Syndrome Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2 South America Restless Legs Syndrome Market Size by Country (2021-2026)
- 10.3 South America Restless Legs Syndrome Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa Restless Legs Syndrome Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2 Middle East & Africa Restless Legs Syndrome Market Size by Country (2021-2026)
- 11.3 Middle East & Africa Restless Legs Syndrome Market Size Forecast by Country (2027-2032)
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst